If you like Johnson & Johnson for its mix of medicine and medical devices, owning the stock directly means living with its specific bumps. Simply Wall St points out that profit margins of 16.2% are lower than last year’s 27.2%, and that a loss of exclusivity for a key drug could squeeze revenue. Holding Johnson & Johnson inside an exchange traded fund such as XLV, VHT or SPMO spreads that kind of issue across many holdings, which also limits how much its wins help your overall returns.
Fresh news gives you something concrete to weigh. On 17 November 2026, Isomorphic Labs raised US$5b, with Johnson & Johnson among the investors, to push computer designed medicine towards clinical trials. That funding round ties Johnson & Johnson more closely to a new way of discovering treatments for conditions like cancer, and it does so through a separate business that funds including XLV, VHT and SPMO can hold alongside many other companies.
| Fund | Johnson & Johnson weight | Rank in fund by weight | 5-year annualised return after fees | Fee | Assets |
|---|---|---|---|---|---|
| State Street Health Care Select Sector SPDR ETF (XLV) | 10.04% | #2 of 64 | 8.7% | 0.08% | US$50.57 billion |
| Vanguard Health Care ETF (VHT) | 8.38% | #2 of 417 | 7.6% | 0.09% | US$23.70 billion |
| Invesco S&P 500 Momentum ETF (SPMO) | 5.44% | #4 of 105 | 15.6% | 0.13% | US$20.81 billion |
Prefer to pick the companies yourself? Start with 37 high quality undervalued stocks.
With about 10% of XLV tied to Johnson & Johnson, each US$1,000 in the fund gives you roughly US$100 in that single company, which is a meaningful slice of your exposure. The rest of XLV is spread across large US health businesses. Pharmaceuticals account for 37.2% of the portfolio and biotechnology a further 19.9%. Health care equipment, life sciences tools and services, and managed care together carry much of what is left. Eli Lilly at 16.75% and AbbVie at 7.64% anchor the top end of the lineup, which puts Johnson & Johnson in heavyweight company but still leaves stock specific risk.
One issue that can worry investors in Johnson & Johnson is the chance of large one off items hitting its financial results, for example from litigation or restructuring. XLV cannot make that risk vanish for Johnson & Johnson itself. It holds that exposure directly. What it can do is balance it with holdings that depend on different therapies, devices and health care services, so a one off charge at Johnson & Johnson may have less impact on the fund than on a single stock portfolio. This gives you breadth across health care but keeps the sector’s own uncertainties.
Not every stock inside XLV is priced the same way. Find out how many of XLV's holdings look undervalued.
VHT looks a lot like XLV, with a similar tilt toward pharmaceuticals at 33.7% and biotechnology at 24.1%, then a mix of health care equipment, life sciences tools and services, managed care and distributors. Johnson & Johnson is the second largest holding at 8.38%, so roughly US$84 of every US$1,000 you invest tracks that stock, which is a clear but not overwhelming slice. Eli Lilly at 14.67% and AbbVie at 6.73% pull more of your money toward large drug developers than XLV, while the fund still spreads the rest across hundreds of health companies.
Profit margins at Johnson & Johnson of 16.2% are well below last year’s 27.2%. VHT cannot erase that pressure inside the business, although its other pharmaceutical, biotech and health care holdings depend on different products and customer bases, so any margin strain at Johnson & Johnson has a smaller direct hit on your overall ETF position. You remain heavily reliant on health care as a whole, and this leaves you tied to the sector’s wider policy and pricing climate.
Uncover whether VHT has kept pace with the market over the past week, year and five years
Apple and Micron Technology dominate the top of SPMO, with semiconductors, technology hardware and related equipment together making up a large share of the portfolio. That pulls your money toward sectors whose fortunes depend on chips, devices and digital services rather than on health alone. Within that mix, Johnson & Johnson is the fourth largest holding at 5.44% of the fund, so each US$1,000 in SPMO puts about US$54 into Johnson & Johnson while the rest tracks a wide spread of S&P 500 stocks with strong price momentum scores.
Loss of exclusivity for STELARA and biosimilar competition could hit revenue from one of Johnson & Johnson’s major products. SPMO holds many companies outside pharmaceuticals, including large allocations to technology and integrated oil and gas, so a product specific shock at Johnson & Johnson would be cushioned by holdings that lean on very different end markets and demand drivers.
Ten companies make up 50.5% of SPMO. Find out which ones, and how much each carries.
Your decision really comes down to how tightly you want to tie Johnson & Johnson to everything else you own. XLV leans hardest into the stock. Around US$100 of every US$1,000 sits there, for a low fee of about US$8 a year on US$10,000, inside a portfolio focused on health care. VHT asks for roughly US$84 out of US$1,000 yet spreads the rest across 417 holdings, far broader than XLV, at only a small extra cost. SPMO gives the lightest Johnson & Johnson tilt at about US$54 per US$1,000 and mixes it with chipmakers and other sectors, which softens any hit if a single drug faces tougher competition. You choose what you are most willing to give up, depth in health or breadth across the market, for your Johnson & Johnson stake and its new push into AI driven drug discovery.
Eli Lilly is the largest holding in both XLV and VHT, so you'd own it either way. Check whether Eli Lilly trades above or below its fair value.
Fund data as of 31 October 2026. Portfolio holdings as of 31 October 2026.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com